Kala Bio (KALA) Shares Outstanding (2016 - 2026)
Kala Bio (KALA) posted Shares Outstanding (Entity) of $11.9 million for Q1 2026, up 7185.92% sequentially from $162966.0 in Q4 2025, and up 9100.89% YoY from $129048.0 in Q1 2025.
Kala Bio (KALA) Shares Outstanding (2016 - 2026) Analysis & Trends
Kala Bio has reported Shares Outstanding (Entity) for 11 years, with the latest figure at $11.9 million in Q1 2026.
- Quarterly Shares Outstanding (Entity) rose 9100.89% year-over-year to $11.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $11.9 million (up 9100.89% YoY) and the FY2025 annual result came in at $162966.0, up 114.65% from the prior year.
- Shares Outstanding (Entity) climbed to $11.9 million in Q1 2026 per KALA's latest filing, from $162966.0 in the prior quarter.
- Over five years, Shares Outstanding (Entity) peaked at $11.9 million in Q1 2026 and troughed at $29038.0 in Q1 2022.
- A 5-year average of $768274.6 and a median of $56329.0 in 2024 frame the typical range for Shares Outstanding (Entity).
- The sharpest annual moves came in 2022 and 2026: Shares Outstanding (Entity) gained 12.2% in 2022, then surged 9100.89% in 2026.
- Over 5 years, Shares Outstanding (Entity) stood at $34139.0 in 2022, then jumped by 61.65% to $55187.0 in 2023, then soared by 37.57% to $75921.0 in 2024, then soared by 114.65% to $162966.0 in 2025, then soared by 7185.92% to $11.9 million in 2026.
- According to Business Quant data, Shares Outstanding (Entity) over the past three periods registered $11.9 million, $162966.0, and $148658.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 253.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 102.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 62.19 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 398.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 111.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 133.61 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 241.70 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 217.35 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 445.06 Mn |
| 10 | Kala Bio | 9.89 Mn | 9.89 Mn | - | 11.87 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 11.87 Mn |
| Dec 31, 2025 | 162,966.00 |
| Sep 30, 2025 | 140,849.00 |
| Jun 30, 2025 | 130,262.00 |
| Mar 31, 2025 | 126,917.00 |
| Dec 31, 2024 | 75,921.00 |
| Sep 30, 2024 | 92,552.00 |
| Jun 30, 2024 | 60,604.00 |
| Mar 31, 2024 | 56,264.00 |
| Dec 31, 2023 | 48,640.00 |
| Sep 30, 2023 | 51,004.00 |
| Jun 30, 2023 | 47,756.00 |
| Mar 31, 2023 | 41,384.00 |
| Dec 31, 2022 | 30,412.00 |
| Sep 30, 2022 | 29,980.00 |
| Jun 30, 2022 | 29,471.00 |
| Mar 31, 2022 | 29,456.00 |
| Dec 31, 2021 | 26,081.00 |
| Sep 30, 2021 | 26,020.00 |
| Jun 30, 2021 | 25,822.00 |